Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/2/2025

Management of Nausea in the Emergency Department

First-Line Antiemetic Agents

  • The American College of Emergency Physicians recommends dopaminergic antagonists, such as haloperidol, risperidone, metoclopramide, or prochlorperazine, as first-line agents for nausea and vomiting in the ED, with ondansetron added as a second agent for refractory cases 1, 2, 3
  • Haloperidol is recommended at a dose of 0.5-2 mg IV/SC/PO every 3-6 hours 1
  • Prochlorperazine is recommended at a dose of 5-10 mg IV/PO every 3-4 hours 1
  • Chlorpromazine is recommended at a dose of 12.5-25 mg IV or 25-50 mg PO every 3-4 hours 1

Second-Line and Adjunctive Agents

  • Ondansetron (4 mg IV) should be added as a second agent when first-line medications are unable to control symptoms 1, 2, 3
  • Dexamethasone is recommended at a dose of 2-8 mg IV/PO every 3-6 hours, particularly useful for bowel obstruction or intracranial hypertension 1
  • Scopolamine is recommended at a dose of 1.5-3 mg topical patch every 72 hours for increased oral secretions 1
  • Lorazepam is recommended at a dose of 0.5-2 mcg IV/PO every 6 hours for anticipatory nausea 1

Special Clinical Scenarios

  • For cyclic vomiting syndrome in the ED, sumatriptan combined with an antiemetic agent (like ondansetron) is recommended 4
  • For chemotherapy-induced nausea and vomiting, a 4-drug regimen is recommended, including olanzapine, NK1 receptor antagonist, 5-HT3 antagonist, and dexamethasone 5

Route of Administration Considerations

  • For actively vomiting patients, consider alternative routes, such as sublingual tablets of ondansetron 4
  • Promethazine and prochlorperazine are available as rectal suppositories 4
  • Sumatriptan can be administered via nasal spray in a head-forward position 4

Cautions and Monitoring

  • Use caution with olanzapine in elderly patients due to risks of sedation and metabolic effects 5